Shares of Lupin surged 10 per cent to Rs 972.50 on the BSE in Tuesday’s intra-day trade, after the drug-maker announced that it has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (US FDA) for its Goa manufacturing facility. The US drug regulator had inspected the facility in September 2021.